Parkinson's disease
Conditions
Interventions
SCAN group:iTBS targeting the individualized SCAN regions + Conventional pharmacotherapy
Effector network group:iTBS targeting the individualized Effector network regions + Conventional pharmacotherapy
Sponsors
Henan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Diagnosed with Idiopathic Parkinson's disease (PD) based on the revised clinical diagnostic criteria of the International Movement Disorder Society (MDS, version 2015) or the Chinese Parkinson's Disease Diagnostic Criteria (version 2016). (2) Aged between 40 and 80 years, with a diagnosis age of >=40 years. (3) Hoehn-Yahr stage between 2 and 4 (inclusive). (4) Stable use of anti-Parkinsonian medications for at least one month prior to enrollment and throughout the study period. (5) Fully informed about the study and provided written informed consent.
Exclusion criteria
Exclusion criteria: (1) Diagnosed with other neurological disorders such as stroke, brain tumor, traumatic brain injury, motor neuron disease, Alzheimer's disease, or multiple sclerosis. (2) Implanted with metallic medical devices such as deep brain stimulators, cochlear implants, or vagus nerve stimulators. (3) Had contraindications for MRI scans, including claustrophobia, tattoos, or the presence of magnetic metallic implants (to be confirmed with a specialist, if necessary). (4) History of epilepsy or a first-degree relative with epilepsy. (5) Received other neuromodulation treatments (e.g., TMS, transcranial electrical stimulation, or transcranial ultrasound stimulation) within 3 months prior to enrollment. (6) Suffering from severe organic diseases (e.g., malignant tumors) with an expected survival time of less than 5 years. (7) Severe language, auditory, visual, or cognitive impairments (MMSE = 17), anxiety (HAMA >= 21), or currently taking antidepressant or anxiolytic medications. (9) Diagnosed with other psychiatric disorders according to DSM-5 criteria. (10) History of alcohol abuse, drug abuse, or other substance abuse. (11) Presence of other abnormalities or conditions deemed unsuitable for participation by the investigator. (12) Inability to complete follow-ups due to geographical or other reasons. (13) Women who are pregnant, breastfeeding, or planning to become pregnant during the study period. (14) Concurrent participation in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MDS Unified-Parkinson Disease Rating Scale (MDS-UPDRS)-?; | — |
Secondary
| Measure | Time frame |
|---|---|
| MDS Unified-Parkinson Disease Rating Scale (MDS-UPDRS)-?;Timed Up and Go Test (TUG);Parkinson’s Disease Questionnaire-39 (PDQ-39); | — |
Countries
China
Contacts
Public ContactMeiyun Wang
Henan Provincial People’s Hospital
Outcome results
None listed